Clinical Trial: Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403370) titled 'Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis' on Jan. 18.

Brief Summary: Olanzapine is an effective antiemetic agent for preventing highly emetogenic regimens-induced nausea and vomiting (HER-INV) in patients receiving highly emetogenic regimens (HER). The optimal dose remains debated, with the standard 10 mg dose often causing significant daytime sedation. Recent evidence suggests that lower doses (2.5 mg and 5 mg) may offer comparable efficacy with improved tolerability. However, no head-to-head randomized controlled trials (RCTs) directly compare all three doses.

Study Start Date: Jan. 18

St...